Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194


High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.

Wang Z, Katsaros D, Biglia N, Shen Y, Fu Y, Loo LWM, Jia W, Obata Y, Yu H.

Breast Cancer Res Treat. 2018 May 29. doi: 10.1007/s10549-018-4839-2. [Epub ahead of print]


A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.

Ghisoni E, Katsaros D, Maggiorotto F, Aglietta M, Vaira M, De Simone M, Mittica G, Giannone G, Robella M, Genta S, Lucchino F, Marocco F, Borella F, Valabrega G, Ponzone R.

J Ovarian Res. 2018 May 30;11(1):42. doi: 10.1186/s13048-018-0415-y.


Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.


High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome.

D'Hondt V, Lacroix-Triki M, Jarlier M, Boissiere-Michot F, Puech C, Coopman P, Katsaros D, Freiss G.

Oncotarget. 2017 Sep 21;8(56):95662-95673. doi: 10.18632/oncotarget.21175. eCollection 2017 Nov 10.


Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.

de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven-Adema KW, Putter H, Creutzberg CL, Smit VTHBM; for PORTEC Study Group.

Ann Oncol. 2018 Feb 1;29(2):424-430. doi: 10.1093/annonc/mdx753.


lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study.

Martini P, Paracchini L, Caratti G, Mello-Grand M, Fruscio R, Beltrame L, Calura E, Sales G, Ravaggi A, Bignotti E, Odicino FE, Sartori E, Perego P, Katsaros D, Craparotta I, Chiorino G, Cagnin S, Mannarino L, Ceppi L, Mangioni C, Ghimenti C, D'Incalci M, Marchini S, Romualdi C.

Clin Cancer Res. 2017 May 1;23(9):2356-2366. doi: 10.1158/1078-0432.CCR-16-1402. Epub 2016 Nov 8.


Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer.

Fu Y, Biglia N, Wang Z, Shen Y, Risch HA, Lu L, Canuto EM, Jia W, Katsaros D, Yu H.

Gynecol Oncol. 2016 Dec;143(3):642-649. doi: 10.1016/j.ygyno.2016.09.021. Epub 2016 Sep 23.


Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2016 Aug;17(8):1114-1126. doi: 10.1016/S1470-2045(16)30120-6. Epub 2016 Jul 7.


A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.

Calura E, Paracchini L, Fruscio R, DiFeo A, Ravaggi A, Peronne J, Martini P, Sales G, Beltrame L, Bignotti E, Tognon G, Milani R, Clivio L, Dell'Anna T, Cattoretti G, Katsaros D, Sartori E, Mangioni C, Ardighieri L, D'Incalci M, Marchini S, Romualdi C.

Ann Oncol. 2016 Aug;27(8):1511-9. doi: 10.1093/annonc/mdw210. Epub 2016 May 18.


Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.

Jean S, Li J, Katsaros D, Wubbenhorst B, Maxwell KN, Fishbein L, McLane MW, Benedetto C, Canuto EM, Mitra N, Zhang L, Nathanson KL, Tanyi JL.

Oncotarget. 2016 Jul 26;7(30):48577-48585. doi: 10.18632/oncotarget.9373.


Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Green JA, Steer C, Berns EM, Casado A, Lambrechts D, Jimeno A.

Target Oncol. 2016 Jun;11(3):429. No abstract available.


Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.

Erriquez J, Olivero M, Mittica G, Scalzo MS, Vaira M, De Simone M, Ponzone R, Katsaros D, Aglietta M, Calogero R, Di Renzo MF, Valabrega G.

Oncotarget. 2016 May 3;7(18):26181-91. doi: 10.18632/oncotarget.8325.


LIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis.

Lu L, Katsaros D, Canuto EM, Biglia N, Risch HA, Yu H.

Gynecol Oncol. 2016 Apr;141(1):121-7. doi: 10.1016/j.ygyno.2015.12.035. Epub 2016 Jan 2.


LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer.

Shen Y, Wang Z, Loo LW, Ni Y, Jia W, Fei P, Risch HA, Katsaros D, Yu H.

Breast Cancer Res Treat. 2015 Dec;154(3):473-82. doi: 10.1007/s10549-015-3632-8. Epub 2015 Nov 13.


Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers.

Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan CX, Zhang D, Yuan H, Hua K, Lu Y, Katsaros D, Huang Q, Montone K, Fan Y, Coukos G, Boyd J, Sood AK, Rebbeck T, Mills GB, Dang CV, Zhang L.

Cancer Cell. 2015 Oct 12;28(4):529-540. doi: 10.1016/j.ccell.2015.09.006.


Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis.

Wang Z, Katsaros D, Shen Y, Fu Y, Canuto EM, Benedetto C, Lu L, Chu WM, Risch HA, Yu H.

PLoS One. 2015 Aug 19;10(8):e0136246. doi: 10.1371/journal.pone.0136246. eCollection 2015.


Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG); Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO); Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO); National Cancer Research Institute (NCRI); Australia New Zealand Gynaecological Oncology Group (ANZGOG); Mario Negri Gynecologic Oncology group (MaNGO).

Target Oncol. 2015 Dec;10(4):583-96. doi: 10.1007/s11523-015-0369-6. Erratum in: Target Oncol. 2016 Jun;11(3):429.


ADP-ribosylation factor-like 4C (ARL4C), a novel ovarian cancer metastasis suppressor, identified by integrated genomics.

Su D, Katsaros D, Xu S, Xu H, Gao Y, Biglia N, Feng J, Ying L, Zhang P, Benedetto C, Yu H.

Am J Transl Res. 2015 Feb 15;7(2):242-56. eCollection 2015.


Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer.

Shen Y, Katsaros D, Loo LW, Hernandez BY, Chong C, Canuto EM, Biglia N, Lu L, Risch H, Chu WM, Yu H.

Oncotarget. 2015 Apr 20;6(11):8579-92.


MicroRNA let-7a modifies the effect of self-renewal gene HIWI on patient survival of epithelial ovarian cancer.

Lu L, Katsaros D, Risch HA, Canuto EM, Biglia N, Yu H.

Mol Carcinog. 2016 Apr;55(4):357-65. doi: 10.1002/mc.22285. Epub 2015 Jan 28.


A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer.

Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang LP, Jean S, Li C, Huang Q, Katsaros D, Montone KT, Tanyi JL, Lu Y, Boyd J, Nathanson KL, Li H, Mills GB, Zhang L.

Cancer Cell. 2014 Sep 8;26(3):344-357. doi: 10.1016/j.ccr.2014.07.009.


Expression and clinical significance of the autophagy proteins BECLIN 1 and LC3 in ovarian cancer.

Valente G, Morani F, Nicotra G, Fusco N, Peracchio C, Titone R, Alabiso O, Arisio R, Katsaros D, Benedetto C, Isidoro C.

Biomed Res Int. 2014;2014:462658. doi: 10.1155/2014/462658. Epub 2014 Jul 17.


Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).

Esposito F, Cecere SC, Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Scalone S, Rabaiotti E, Salutari V, Cormio G, Canuto EM, Greggi S, Savarese A, Marinaccio M, Scollo P, Santeufemia DA, Sacco C, Facchini G, Pignata S.

Oncology. 2014;86(5-6):351-8. doi: 10.1159/000358730. Epub 2014 Jun 12.


Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators.

Lancet Oncol. 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28.


Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.

Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E.

J Clin Oncol. 2014 Feb 1;32(4):320-6. doi: 10.1200/JCO.2013.50.5669. Epub 2013 Dec 23.


Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma.

Benedetti Panici P, Basile S, Salerno MG, Di Donato V, Marchetti C, Perniola G, Palagiano A, Perutelli A, Maneschi F, Lissoni AA, Signorelli M, Scambia G, Tateo S, Mangili G, Katsaros D, Campagnutta E, Donadello N, Greggi S, Melpignano M, Raspagliesi F, Cormio G, Grassi R, Franchi M, Giannarelli D, Fossati R, Torri V, Crocè C, Mangioni C.

Am J Obstet Gynecol. 2014 Apr;210(4):363.e1-363.e10. doi: 10.1016/j.ajog.2013.12.025. Epub 2013 Dec 19.


MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities.

Calura E, Fruscio R, Paracchini L, Bignotti E, Ravaggi A, Martini P, Sales G, Beltrame L, Clivio L, Ceppi L, Di Marino M, Fuso Nerini I, Zanotti L, Cavalieri D, Cattoretti G, Perego P, Milani R, Katsaros D, Tognon G, Sartori E, Pecorelli S, Mangioni C, D'Incalci M, Romualdi C, Marchini S.

Clin Cancer Res. 2013 Aug 1;19(15):4114-23. doi: 10.1158/1078-0432.CCR-13-0360. Epub 2013 Jun 13.


An insulin-like growth factor-II intronic variant affects local DNA conformation and ovarian cancer survival.

Lu L, Risch E, Deng Q, Biglia N, Picardo E, Katsaros D, Yu H.

Carcinogenesis. 2013 Sep;34(9):2024-30. doi: 10.1093/carcin/bgt168. Epub 2013 May 14.


Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer.

Ying L, Su D, Zhu J, Ma S, Katsaros D, Yu H.

Oncol Lett. 2013 Apr;5(4):1315-1320. Epub 2013 Jan 18.


The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer.

Hu X, Guo J, Zheng L, Li C, Zheng TM, Tanyi JL, Liang S, Benedetto C, Mitidieri M, Katsaros D, Zhao X, Zhang Y, Huang Q, Zhang L.

Mol Cancer Res. 2013 Mar;11(3):240-50. doi: 10.1158/1541-7786.MCR-12-0432. Epub 2013 Jan 21.


Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer.

Lu L, Zhu G, Zhang C, Deng Q, Katsaros D, Mayne ST, Risch HA, Mu L, Canuto EM, Gregori G, Benedetto C, Yu H.

Breast Cancer Res Treat. 2012 Dec;136(3):875-83. doi: 10.1007/s10549-012-2314-z. Epub 2012 Nov 3.


Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer.

Lu L, Katsaros D, Mayne ST, Risch HA, Benedetto C, Canuto EM, Yu H.

Carcinogenesis. 2012 Nov;33(11):2119-25. doi: 10.1093/carcin/bgs243. Epub 2012 Jul 20.


The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer.

Marchini S, Poynor E, Barakat RR, Clivio L, Cinquini M, Fruscio R, Porcu L, Bussani C, D'Incalci M, Erba E, Romano M, Cattoretti G, Katsaros D, Koff A, Luzzatto L.

Clin Cancer Res. 2012 Aug 15;18(16):4313-24. Epub 2012 Jun 25.


An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.

Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D, Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H, Colombo N.

Int J Gynecol Cancer. 2012 Jun;22(5):792-800. doi: 10.1097/IGC.0b013e318251051a.


Lin-28 homologue A (LIN28A) promotes cell cycle progression via regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homolog A (CDC25A) expression in cancer.

Li N, Zhong X, Lin X, Guo J, Zou L, Tanyi JL, Shao Z, Liang S, Wang LP, Hwang WT, Katsaros D, Montone K, Zhao X, Zhang L.

J Biol Chem. 2012 May 18;287(21):17386-97. doi: 10.1074/jbc.M111.321158. Epub 2012 Mar 30.


PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer.

Su D, Xu H, Feng J, Gao Y, Gu L, Ying L, Katsaros D, Yu H, Xu S, Qi M.

J Transl Med. 2012 Feb 27;10:31. doi: 10.1186/1479-5876-10-31.


Favorable outcome associated with an IGF-1 ligand signature in breast cancer.

Mu L, Tuck D, Katsaros D, Lu L, Schulz V, Perincheri S, Menato G, Scarampi L, Harris L, Yu H.

Breast Cancer Res Treat. 2012 May;133(1):321-31. doi: 10.1007/s10549-012-1952-5.


Variation in gynecological oncology follow-up practice: attributable to cancer centers or to patient characteristics? A Piedmont Regional Oncology Network Study.

Fuso L, Evangelista A, Pagano E, Piovano E, Perotto S, Mazzola S, Bertoldo E, La Porta MR, Rosmino C, Furbatto G, Abate S, Di Costanzo G, Trossarelli G, Baù MG, Carnino F, Gambaro G, Piantanida P, Alabiso O, Galletto L, Zavallone L, Rossi A, Barbero M, Tessa M, Katsaros D, Danese S, Brignolo P, Gorzegno G, Grillo R, Apolone G, Ciccone G.

Tumori. 2011 Sep-Oct;97(5):551-8. doi: 10.1700/989.10710.


A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.

Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.

Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5.


A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer.

Li N, Kaur S, Greshock J, Lassus H, Zhong X, Wang Y, Leminen A, Shao Z, Hu X, Liang S, Katsaros D, Huang Q, Bützow R, Weber BL, Coukos G, Zhang L.

Cancer Res. 2012 Jan 1;72(1):154-64. doi: 10.1158/0008-5472.CAN-11-2484. Epub 2011 Nov 4.


Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1.

Zeng H, Irwin ML, Lu L, Risch H, Mayne S, Mu L, Deng Q, Scarampi L, Mitidieri M, Katsaros D, Yu H.

Breast Cancer Res Treat. 2012 May;133(1):127-35. doi: 10.1007/s10549-011-1716-7. Epub 2011 Aug 12.


Netrin-1 overexpression is predictive of ovarian malignancies.

Papanastasiou AD, Pampalakis G, Katsaros D, Sotiropoulou G.

Oncotarget. 2011 May;2(5):363-7.


Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome.

Lu L, Zhang C, Zhu G, Irwin M, Risch H, Menato G, Mitidieri M, Katsaros D, Yu H.

Breast Cancer Res. 2011 Jun 6;13(3):R56. doi: 10.1186/bcr2893.


Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study.

Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Sorio R, Rabaiotti E, Scambia G, Cormio G, Scarampi L, Greggi S, Savarese A, Marinaccio M, Scollo P, Pignata S.

Int J Gynecol Cancer. 2011 Aug;21(6):1063-70. doi: 10.1097/IGC.0b013e318218f270.


Novel surface targets and serum biomarkers from the ovarian cancer vasculature.

Sasaroli D, Gimotty PA, Pathak HB, Hammond R, Kougioumtzidou E, Katsaros D, Buckanovich R, Devarajan K, Sandaltzopoulos R, Godwin AK, Scholler N, Coukos G.

Cancer Biol Ther. 2011 Aug 1;12(3):169-80. Epub 2011 Aug 1.


MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management.

Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H, Katsaros D.

Gynecol Oncol. 2011 Aug;122(2):366-71. doi: 10.1016/j.ygyno.2011.04.033. Epub 2011 May 14.


Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.

Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, Testa JR, Nathanson KL, Gimotty PA, Coukos G, Weber BL, Degenhardt Y.

Genes Chromosomes Cancer. 2011 Aug;50(8):606-18. doi: 10.1002/gcc.20883. Epub 2011 May 11.


Clinical trials in recurrent ovarian cancer.

Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup.

Int J Gynecol Cancer. 2011 May;21(4):771-5. doi: 10.1097/IGC.0b013e31821bb8aa. Review.


Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.

Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Fuso Nerini I, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, Buda A, Romualdi C, D'Incalci M.

Lancet Oncol. 2011 Mar;12(3):273-85. doi: 10.1016/S1470-2045(11)70012-2. Epub 2011 Feb 21.


The proper use of multimodality treatment in locally advanced cervical cancer.

Katsaros D, Gribaudo S.

Gynecol Oncol. 2011 May 1;121(2):422-3; author reply 422. doi: 10.1016/j.ygyno.2010.12.346. Epub 2011 Feb 4. No abstract available.


Supplemental Content

Loading ...
Support Center